The European Medicines Agency (EMA) has announced new regulations concerning paediatric investigation plans (PIPs). These regulations aim to include children more effectively in drug development processes. Taking into account the specific needs of children, the EMA emphasized the importance of paediatric trials in assessing the safety and efficacy of new medicines.
The new regulations aim to help trial sites better prepare and submit their paediatric investigation plans. In addition, the necessary steps will be taken to accelerate the approval processes for these plans and to ensure more transparent communication. The EMA stated that these regulations will contribute to the development of more effective treatment options for children's health.
Implications for the Clinical Trials Sector and Sponsors in Türkiye:
These new regulations will have significant implications for the clinical trials sector in Türkiye. In particular, trial sites and sponsors in Türkiye will be required to comply with the new criteria set by the EMA. The growing importance of paediatric trials will necessitate a greater focus on the paediatric population in clinical trial projects in Türkiye.
Sponsors will need to be provided with more information and support regarding the preparation and implementation of paediatric investigation plans. In this context, it is essential for clinical trial sites in Türkiye to develop the necessary infrastructure and expertise to comply with the EMA's new regulations.
Conclusion and Call to Action:
With its 29 years of experience, Omega CRO holds a leading position in the clinical trials sector in Türkiye. With our HelixLab and Omega Genetics laboratories, OmegaCare providing home healthcare services, our biorepository services, and our advanced technologies (TURP, IWRS), we offer sponsors comprehensive support in adapting to current regulatory developments of this kind. Contact us for any information and support you may need; let us work together towards a healthier future.